LONDON--(BUSINESS WIRE)--Immune Targeting Systems (ITS) Limited (“ITS”), the company developing synthetic vaccines for mutating viruses, today announced it had closed its series-A equity funding round for £3.5m (€5.2m, $7.0m). This is ITS’s first significant funding round with major Global life science and specialist investors which included the Novartis Venture Fund (US & Basel) www.venturefund.novartis.com; Truffle Capital (France) www.truffle.com; HealthCap (Sweden) www.healthcap.se; and the London Technology Fund (UK) www.londontechnologyfund.com. The London Development Agency will also be contributing an Exceptional Development Project award of £500,000 (€0.74m, $1.0m) under the Grant for Research and Development scheme.
